The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
risk of recurrence in patients with low-grade serous ovarian carcinoma
Timeframe: two years
number of patients with objective tumor response after receiving chemotherapy
Timeframe: 6 months
number of patients with objective tumor response after receiving hormone therapy
Timeframe: 6 months
number of patients with objective tumor response after receiving combination hormonal and chemotherapy
Timeframe: 6 months
progression free survival
Timeframe: 2 years
overall survival
Timeframe: 5 years